Navigation Links
Viral infections in infancy are not associated with wheezing symptoms in later childhood
Date:5/23/2012

ATS 2012, SAN FRANCISCO The number of viral infections during infancy is not associated with wheezing later in childhood, according to a new study from researchers in the Netherlands. While viral illnesses with wheezing in infancy predicted wheezing later in childhood, this association was due in part to decreased neonatal lung function.

"Viral infections in infancy, particularly rhinovirus, are thought to be a risk factor for later asthma development, but it is unclear whether this association is due to the viruses themselves or whether rhinovirus-associated wheeze is merely an indicator of disease susceptibility," said Anne van der Gugten, MD, a researcher at the University Medical Center Utrecht. "Accordingly, we examined the association between viruses during the first year of life independent of symptoms and the subsequent development of wheezing symptoms in childhood."

The results of the study will be presented at the ATS 2012 International Conference in San Francisco.

In the prospective, population-based birth cohort study, 96 children were followed from infancy through age four. Nose and throat swabs were collected at the beginning of every month during the first year of life, independent of the occurrence of symptoms. Pre-symptomatic lung function was assessed at the age of two months using the single occlusion technique.

Of 96 children, 13 (13.5%) had wheezing illnesses at age four. Compared to children without wheezing at age four, those with wheezing had decreased neonatal lung function. Children with wheezing at age four had a median of four human rhinovirus (HRV) infections in their first year, compared with a median of five among children without wheezing.

Neither the number of HRV infections in infancy nor the number of viral infections in general were associated with an increased risk of wheezing at age four. While a higher number of viral episodes with wheezing or a higher number of HRV episodes with wheezing was associated with an increased risk of wheezing at age four, these associations were not significant after adjustment for neonatal lung function.

"A number of prospective studies in high-risk cohorts have shown that viral wheezing illnesses, especially those caused by rhinovirus, are the most important predictors of the subsequent development of wheezing or asthma in childhood," said Dr. van der Gugten, "but it is unclear if rhinovirus is causally related to the development of asthma."

"Our study is the first to examine the association between viruses in infancy independent of symptoms and wheezing symptoms in childhood," said Dr. van der Gugten. "Our findings indicate that viral infections by themselves may not be associated with the development of asthma, but that children with reduced neonatal lung function are prone to experience wheezing during viral infections in infancy and to have asthma in childhood."

"Future research into the relationship between rhinovirus and wheezing disorders should account for factors that might modify this relationship, including neonatal lung function," Dr. van der Gugten concluded.


'/>"/>

Contact: Nathaniel Dunford
ndunford@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. New Study: Improved Immune System with Gene-Eden, a Natural Antiviral Supplement that Targets Chronic Viruses
2. Bipartisan Capitol Hill Media Event: Health Experts, Lawmakers to Urge Federal Government to Fix the Funding Failure for Chronic Viral Hepatitis
3. Acupuncture may be an effective treatment for post-viral infection loss of smell
4. UNC study offers first clinical evidence of anti-cancer drug triggering viral infection
5. Viral Infection Could Be Marker for Type 1 Diabetes
6. Antiviral therapy during compensated cirrhosis most cost-effective approach
7. Longer Antiviral Therapy Reduces Lung Transplant Complications
8. Antiretrovirals During Breast-Feeding Shield Babies From HIV, Study Shows
9. Viral protein structure study offers HIV therapy hope
10. Texas A&M researcher explains how embryo fights retroviral infection
11. Vanishing bile duct syndrome secondary to anti-retroviral therapy in HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... D.C., for the 49th Congress of the International Society of Paediatric Oncology ... the Center for Cancer and Blood Disorders at Children’s National, and Stephen ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... (HLA), the nation's first interactive health literacy software tool, and the Cancer Patient ... aspects of cancer patient education, today announce a new strategic alliance. , ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Dining at the University of California Berkeley, and other leading institutions in announcing ... buying power of institutions to change the way animals are raised for food. ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... their devotion to personalized service, SMP Pharmacy Solutions announces their ... South Florida Business Journal,s 50 Fastest-Growing Companies, and listed for ... specialty pharmacy has found its niche.  To that end, the ... by SFBJ as the 2017 Power Leader in Health Care. ... award in October, Bardisa said of the three achievements, "It,s ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology: